Cancer Drugs Market Size, Trends & Forecast (2025-2031) | Growth at 12.6% CAGR
Cancer Drugs Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, and Other Therapy Types), By Indications (Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Ducts Cancer, Thyroid Cancer, and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Stores), and Geography
- Status : Published
- Report Code : TIPRE00040984
- Category : Life Sciences
- No. of Pages : 277
- Available Report Formats :
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Bristol-Myers Squibb Co.; AbbVie Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca Plc; Merck KGaA; Novartis AG; Astellas Pharma Inc.; and Eli Lilly and Co. are among the key players operating in the cancer drugs market.
The cancer drugs market is estimated to register a CAGR of 12.6% during the forecast period.
The cancer drugs market is estimated to reach US$ 516.15 billion by 2031.
The growing burden of breast and lung cancer, and surging investments in oncology research, are among the noteworthy factors contributing to the market growth.
North America dominated the market in 2024.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. Cancer Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in Value Chain
5. Cancer Drugs Market – Key Market Dynamics
5.1 Cancer Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Growing Burden of Breast and Lung Cancer
5.2.2 Surging Investments in Oncology Research
5.3 Market Restraints
5.3.1 High Cost of Treatment
5.4 Market Opportunities
5.4.1 Increased Support from Government and Private Organizations
5.5 Future Trends
5.5.1 Preference for Personalized Medicine
5.6 Impact of Drivers and Restraints:
6. Cancer Drugs Market – Global Market Analysis
6.1 Cancer Drugs Market Revenue (US$ Million), 2021–2031
6.2 Cancer Drugs Market Forecast Analysis
7. Cancer Drugs Market Analysis – by Therapy Types
7.1 Chemotherapy
7.1.1 Overview
7.1.2 Chemotherapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.2 Targeted Therapy
7.2.1 Overview
7.2.2 Targeted Therapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.4 Hormonal Therapy
7.4.1 Overview
7.4.2 Hormonal Therapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.5 Other Therapy Types
7.5.1 Overview
7.5.2 Other Therapy Types: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8. Cancer Drugs Market Analysis – by Indications
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.2 Lung Cancer
8.2.1 Overview
8.2.2 Lung Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.4 Colorectal Cancer
8.4.1 Overview
8.4.2 Colorectal Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.5 Prostate Cancer
8.5.1 Overview
8.5.2 Prostate Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.6 Stomach Cancer
8.6.1 Overview
8.6.2 Stomach Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.7 Cervical Cancer
8.7.1 Overview
8.7.2 Cervical Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Ducts Cancer
8.8.1 Overview
8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.9 Thyroid Cancer
8.9.1 Overview
8.9.2 Thyroid Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.10 Other Indications
8.10.1 Overview
8.10.2 Other Indications: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9. Cancer Drugs Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Overview
9.1.2 Hospital Pharmacies: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.2 Retail Pharmacies
9.2.1 Overview
9.2.2 Retail Pharmacies: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.3 Online Stores
9.3.1 Overview
9.3.2 Online Stores: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10. Cancer Drugs Market – Geographical Analysis
10.1 Overview
10.2 North America
10.2.1 North America Cancer Drugs Market Overview
10.2.2 North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3 North America: Cancer Drugs Market Share – by Therapy Types
10.2.3.1 North America: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.2.4 North America: Cancer Drugs Market Share – by Indications
10.2.4.1 North America: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.2.5 North America: Cancer Drugs Market Share – by Distribution Channel
10.2.5.1 North America: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.2.6 North America: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.2.6.1 North America: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.2.6.2 United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.6.2.1 United States: Cancer Drugs Market Share – by Therapy Types
10.2.6.2.2 United States: Cancer Drugs Market Share – by Indications
10.2.6.2.3 United States: Cancer Drugs Market Share – by Distribution Channel
10.2.6.3 Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.6.3.1 Canada: Cancer Drugs Market Share – by Therapy Types
10.2.6.3.2 Canada: Cancer Drugs Market Share – by Indications
10.2.6.3.3 Canada: Cancer Drugs Market Share – by Distribution Channel
10.2.6.4 Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.6.4.1 Mexico: Cancer Drugs Market Share – by Therapy Types
10.2.6.4.2 Mexico: Cancer Drugs Market Share – by Indications
10.2.6.4.3 Mexico: Cancer Drugs Market Share – by Distribution Channel
10.3 Europe
10.3.1 Europe Cancer Drugs Market Overview
10.3.2 Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3 Europe: Cancer Drugs Market Share – by Therapy Types
10.3.3.1 Europe: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.3.4 Europe: Cancer Drugs Market Share – by Indications
10.3.4.1 Europe: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.3.5 Europe: Cancer Drugs Market Share – by Distribution Channel
10.3.5.1 Europe: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.3.6 Europe: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.3.6.1 Europe: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.3.6.2 Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.2.1 Germany: Cancer Drugs Market Share – by Therapy Types
10.3.6.2.2 Germany: Cancer Drugs Market Share – by Indications
10.3.6.2.3 Germany: Cancer Drugs Market Share – by Distribution Channel
10.3.6.3 United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.3.1 United Kingdom: Cancer Drugs Market Share – by Therapy Types
10.3.6.3.2 United Kingdom: Cancer Drugs Market Share – by Indications
10.3.6.3.3 United Kingdom: Cancer Drugs Market Share – by Distribution Channel
10.3.6.4 France: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.4.1 France: Cancer Drugs Market Share – by Therapy Types
10.3.6.4.2 France: Cancer Drugs Market Share – by Indications
10.3.6.4.3 France: Cancer Drugs Market Share – by Distribution Channel
10.3.6.5 Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.5.1 Italy: Cancer Drugs Market Share – by Therapy Types
10.3.6.5.2 Italy: Cancer Drugs Market Share – by Indications
10.3.6.5.3 Italy: Cancer Drugs Market Share – by Distribution Channel
10.3.6.6 Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.6.1 Spain: Cancer Drugs Market Share – by Therapy Types
10.3.6.6.2 Spain: Cancer Drugs Market Share – by Indications
10.3.6.6.3 Spain: Cancer Drugs Market Share – by Distribution Channel
10.3.6.7 Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.6.7.1 Rest of Europe: Cancer Drugs Market Share – by Therapy Types
10.3.6.7.2 Rest of Europe: Cancer Drugs Market Share – by Indications
10.3.6.7.3 Rest of Europe: Cancer Drugs Market Share – by Distribution Channel
10.4 Asia Pacific
10.4.1 Asia Pacific Cancer Drugs Market Overview
10.4.2 Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3 Asia Pacific: Cancer Drugs Market Share – by Therapy Types
10.4.3.1 Asia Pacific: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.4.4 Asia Pacific: Cancer Drugs Market Share – by Indications
10.4.4.1 Asia Pacific: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.4.5 Asia Pacific: Cancer Drugs Market Share – by Distribution Channel
10.4.5.1 Asia Pacific: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.4.6 Asia Pacific: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.4.6.1 Asia Pacific: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.4.6.2 China: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.2.1 China: Cancer Drugs Market Share – by Therapy Types
10.4.6.2.2 China: Cancer Drugs Market Share – by Indications
10.4.6.2.3 China: Cancer Drugs Market Share – by Distribution Channel
10.4.6.3 Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.3.1 Japan: Cancer Drugs Market Share – by Therapy Types
10.4.6.3.2 Japan: Cancer Drugs Market Share – by Indications
10.4.6.3.3 Japan: Cancer Drugs Market Share – by Distribution Channel
10.4.6.4 India: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.4.1 India: Cancer Drugs Market Share – by Therapy Types
10.4.6.4.2 India: Cancer Drugs Market Share – by Indications
10.4.6.4.3 India: Cancer Drugs Market Share – by Distribution Channel
10.4.6.5 South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.5.1 South Korea: Cancer Drugs Market Share – by Therapy Types
10.4.6.5.2 South Korea: Cancer Drugs Market Share – by Indications
10.4.6.5.3 South Korea: Cancer Drugs Market Share – by Distribution Channel
10.4.6.6 Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.6.1 Australia: Cancer Drugs Market Share – by Therapy Types
10.4.6.6.2 Australia: Cancer Drugs Market Share – by Indications
10.4.6.6.3 Australia: Cancer Drugs Market Share – by Distribution Channel
10.4.6.7 Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.6.7.1 Rest of APAC: Cancer Drugs Market Share – by Therapy Types
10.4.6.7.2 Rest of APAC: Cancer Drugs Market Share – by Indications
10.4.6.7.3 Rest of APAC: Cancer Drugs Market Share – by Distribution Channel
10.5 Middle East and Africa
10.5.1 Middle East and Africa Cancer Drugs Market Overview
10.5.2 Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.3 Middle East and Africa: Cancer Drugs Market Share – by Therapy Types
10.5.3.1 Middle East and Africa: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.5.4 Middle East and Africa: Cancer Drugs Market Share – by Indications
10.5.4.1 Middle East and Africa: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.5.5 Middle East and Africa: Cancer Drugs Market Share – by Distribution Channel
10.5.5.1 Middle East and Africa: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.5.6 Middle East and Africa: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.5.6.1 Middle East and Africa: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.5.6.2 Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.6.2.1 Turkey: Cancer Drugs Market Share – by Therapy Types
10.5.6.2.2 Turkey: Cancer Drugs Market Share – by Indications
10.5.6.2.3 Turkey: Cancer Drugs Market Share – by Distribution Channel
10.5.6.3 GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.6.3.1 GCC Countries: Cancer Drugs Market Share – by Therapy Types
10.5.6.3.2 GCC Countries: Cancer Drugs Market Share – by Indications
10.5.6.3.3 GCC Countries: Cancer Drugs Market Share – by Distribution Channel
10.5.6.4 South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.6.4.1 South Africa: Cancer Drugs Market Share – by Therapy Types
10.5.6.4.2 South Africa: Cancer Drugs Market Share – by Indications
10.5.6.4.3 South Africa: Cancer Drugs Market Share – by Distribution Channel
10.5.6.5 Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.6.5.1 Rest of Middle East and Africa: Cancer Drugs Market Share – by Therapy Types
10.5.6.5.2 Rest of Middle East and Africa: Cancer Drugs Market Share – by Indications
10.5.6.5.3 Rest of Middle East and Africa: Cancer Drugs Market Share – by Distribution Channel
10.6 South and Central America
10.6.1 South and Central America Cancer Drugs Market Overview
10.6.2 South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.6.3 South and Central America: Cancer Drugs Market Share – by Therapy Types
10.6.3.1 South and Central America: Cancer Drugs Market– Revenue and Forecast Analysis – by Therapy Types
10.6.4 South and Central America: Cancer Drugs Market Share – by Indications
10.6.4.1 South and Central America: Cancer Drugs Market– Revenue and Forecast Analysis – by Indications
10.6.5 South and Central America: Cancer Drugs Market Share – by Distribution Channel
10.6.5.1 South and Central America: Cancer Drugs Market– Revenue and Forecast Analysis – by Distribution Channel
10.6.6 South and Central America: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.6.6.1 South and Central America: Cancer Drugs Market – Revenue and Forecast Analysis – by Country
10.6.6.2 Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.6.6.2.1 Brazil: Cancer Drugs Market Share – by Therapy Types
10.6.6.2.2 Brazil: Cancer Drugs Market Share – by Indications
10.6.6.2.3 Brazil: Cancer Drugs Market Share – by Distribution Channel
10.6.6.3 Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.6.6.3.1 Argentina: Cancer Drugs Market Share – by Therapy Types
10.6.6.3.2 Argentina: Cancer Drugs Market Share – by Indications
10.6.6.3.3 Argentina: Cancer Drugs Market Share – by Distribution Channel
10.6.6.4 Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.6.6.4.1 Rest of South and Central America: Cancer Drugs Market Share – by Therapy Types
10.6.6.4.2 Rest of South and Central America: Cancer Drugs Market Share – by Indications
10.6.6.4.3 Rest of South and Central America: Cancer Drugs Market Share – by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Bristol-Myers Squibb Co
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 AbbVie Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Astellas Pharma Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Eli Lilly and Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Novartis AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Merck KGaA
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 AstraZeneca
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Pfizer Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 F. Hoffmann-La Roche Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Johnson & Johnson
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About Us
14.2 List of Abbreviations
List of Tables
Table 1. Cancer Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Table 4. Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 5. Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 6. Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 7. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 8. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 9. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 10. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 11. United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 12. United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 13. United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 14. Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 15. Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 16. Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 17. Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 18. Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 19. Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 20. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 21. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 22. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 23. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 24. Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 25. Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 26. Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 27. United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 28. United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 29. United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 30. France: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 31. France: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 32. France: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 33. Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 34. Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 35. Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 36. Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 37. Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 38. Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 39. Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 40. Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 41. Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 42. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 43. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 44. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 45. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 46. China: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 47. China: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 48. China: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 49. Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 50. Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 51. Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 52. India: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 53. India: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 54. India: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 55. South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 56. South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 57. South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 58. Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 59. Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 60. Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 61. Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 62. Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 63. Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 64. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 65. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 66. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 67. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 68. Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 69. Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 70. Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 71. GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 72. GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 73. GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 74. South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 75. South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 76. South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 77. Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 78. Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 79. Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 80. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
Table 81. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
Table 82. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
Table 83. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 84. Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 85. Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 86. Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 87. Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 88. Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 89. Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 90. Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Therapy Types
Table 91. Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Indications
Table 92. Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million) – by Distribution Channel
Table 93. List of Abbreviations
List of Figures
Figure 1. Cancer Drugs Market Segmentation – Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Cancer Drugs Market Revenue (US$ Million), 2021–2031
Figure 5. Cancer Drugs Market Share (%) – by Therapy Types (2024 and 2031)
Figure 6. Chemotherapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 7. Targeted Therapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 8. Immunotherapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 9. Hormonal Therapy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 10. Other Therapy Types: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 11. Cancer Drugs Market Share (%) – by Indications (2024 and 2031)
Figure 12. Blood Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 13. Lung Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 14. Breast Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 15. Colorectal Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 16. Prostate Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 17. Stomach Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 18. Cervical Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 19. Liver and Intrahepatic Bile Ducts Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 20. Thyroid Cancer: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 21. Other Indications: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 22. Cancer Drugs Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 23. Hospital Pharmacies: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 24. Retail Pharmacies: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 25. Online Stores: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 26. Cancer Drugs Market Regional Share, 2024 and 2031 (%)
Figure 27. North America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 28. North America: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 29. North America: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 30. North America: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 31. North America: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 32. United States: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 33. Canada: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 34. Mexico: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 35. Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 36. Europe: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 37. Europe: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 38. Europe: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 39. Europe: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 40. Germany: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 41. United Kingdom: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 42. France: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 43. Italy: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 44. Spain: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 45. Rest of Europe: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 46. Asia Pacific: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 47. Asia Pacific: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 48. Asia Pacific: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 49. Asia Pacific: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 50. Asia Pacific: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 51. China: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 52. Japan: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 53. India: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 54. South Korea: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 55. Australia: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 56. Rest of APAC: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 57. Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 58. Middle East and Africa: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 59. Middle East and Africa: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 60. Middle East and Africa: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 61. Middle East and Africa: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 62. Turkey: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 63. GCC Countries: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 64. South Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 65. Rest of Middle East and Africa: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 66. South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031(US$ Million)
Figure 67. South and Central America: Cancer Drugs Market Share – by Therapy Types (2024 and 2031)
Figure 68. South and Central America: Cancer Drugs Market Share – by Indications (2024 and 2031)
Figure 69. South and Central America: Cancer Drugs Market Share – by Distribution Channel (2024 and 2031)
Figure 70. South and Central America: Cancer Drugs Market Share – Key Countries, 2024 and 2031 (%)
Figure 71. Brazil: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 72. Argentina: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 73. Rest of South and Central America: Cancer Drugs Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 74. Heat Map Analysis by Key Players
Figure 75. Company Positioning and Concentration
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For